Evaluate Vantage Homepage
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
PTC’s confirmatory Duchenne data resurrect US hopes
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.
Medtech
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Company Events
Karuna seeks a novel schizophrenia mechanism
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Interviews
Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
Asco 2022 – Can Daiichi do it again?
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.